Atricure reports fourth quarter 2023 and full year 2023 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced fourth quarter 2023 and full year 2023 financial results. “our 2023 results showcase the broad-based expansion of our many growth drivers, balanced by disciplined investments as we make progress towards sustained profitability,” said michael carrel, presiden.
ATRC Ratings Summary
ATRC Quant Ranking